

GLAXOSMITHKLINE PLC  
Form 6-K  
February 09, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 09 February 2017

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Philip Hampton
  - b) Position/status Non-Executive Chairman
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
    - ISIN: GB0009252882
    - Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent
  - b) Nature of the transaction Non-Executive Directors for the period of service from 1 October 2016 to 31 December 2016.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.55	2,813.505
n/a (single transaction)	
  - d) Aggregated information
 

Aggregated volume	Price
  - e) Date of the transaction 2017-02-08
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Professor Sir Roy Anderson
  - b) Position/status Independent Non-Executive Director
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
- 3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2016 to 31 December 2016.
c) Price(s) and volume(s)	Price(s)      Volume(s) £15.55      462.219 n/a (single transaction)
d) Aggregated information	
Aggregated volume	Price
e) Date of the transaction	2017-02-08
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr Vindi Banga
b) Position/status	Senior Independent Non-Executive Director
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for

the period of service from 1  
October 2016 to 31  
December 2016.

c) Price(s) and volume(s)  
Price(s)      Volume(s)  
£15.55      1,848.875  
n/a (single transaction)

Aggregated information

d)  
Aggregated volume Price

e) Date of the transaction      2017-02-08

f) Place of the transaction      n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name      Dr Vivienne Cox  
b) Position/status      Independent Non-Executive  
Director

c) Initial notification/  
amendment      Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name      GlaxoSmithKline plc  
b) LEI      5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

a) Description of the financial instrument      Ordinary shares of 25 pence  
each ('Ordinary Shares')

b) Nature of the transaction      ISIN: GB0009252882  
Acquisition of notional  
Ordinary Shares under the  
share allocation arrangements  
for Independent  
Non-Executive Directors for  
the period of service from 1  
October 2016 to 31  
December 2016.

c) Price(s) and volume(s)  
Price(s)      Volume(s)  
£15.55      341.640  
n/a (single transaction)

Aggregated information

d)  
Aggregated volume Price

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

e) Date of the transaction 2017-02-08  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms Lynn Elsenhans  
 b) Position/status Independent Non-Executive Director  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
 b) Nature of the transaction ISIN: US37733W1053  
 Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2016 to 31 December 2016.  
 c) Price(s) and volume(s)  

Price(s)	Volume(s)
\$39.47	1,426.401
n/a (single transaction)	

d) Aggregated information  
 Aggregated volume Price

e) Date of the transaction 2017-02-08  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms Judy Lewent  
 b) Position/status Independent Non-Executive Director

- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depositary Shares ('ADSs')
- ISIN: US37733W1053
- Acquisition of notional ADSs under the share allocation arrangements for Independent
- b) Nature of the transaction Non-Executive Directors for the period of service from 1 October 2016 to 31 December 2016.
- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| \$39.47                  | 540.304   |
| n/a (single transaction) |           |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2017-02-08
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr Urs Rohner
- b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 October 2016 to 31 December 2016.
c) Price(s) and volume(s)	Price(s)      Volume(s) £15.55      422.026 n/a (single transaction)
d) Aggregated information	
Aggregated volume Price	
e) Date of the transaction	2017-02-08
f) Place of the transaction	n/a

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 09, 2017

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc